Skip to main content
Clinical Trials/NCT06739512
NCT06739512
Not yet recruiting
Not Applicable

Efficacy and Safety of Pulsed Field Ablation in Three Different Substrate Ablation Strategies for Persistent Atrial Fibrillation: a Multicenter Randomized Controlled Trial

Shanghai Chest Hospital1 site in 1 country600 target enrollmentDecember 25, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation (AF)
Sponsor
Shanghai Chest Hospital
Enrollment
600
Locations
1
Primary Endpoint
Freedom from Atrial Arrhythmia Recurrence at 12 Months
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of pulsed field ablation (PFA) in patients with persistent atrial fibrillation (PeAF). We will compare three distinct substrate ablation strategies: anatomical guided ablation (ANAT group), electrogram guided ablation (EGM group), and extensive electro-anatomical guided ablation (EXT group). The study seeks to identify which ablation strategy yields the highest efficacy and safety profiles to potentially guide future clinical practice in the management of PeAF.

Registry
clinicaltrials.gov
Start Date
December 25, 2024
End Date
December 1, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Xu Liu

MD

Shanghai Chest Hospital

Eligibility Criteria

Inclusion Criteria

  • Adults aged 18-80 years diagnosed with persistent atrial fibrillation.
  • Ineffectiveness or intolerance to at least one Class I or III anti-arrhythmic drug.

Exclusion Criteria

  • Major valvular diseases needing surgical intervention.
  • Presence of a left atrial thrombus on recent imaging.
  • Recent myocardial infarction or severe heart failure (LVEF ≤ 30%).
  • Current Severe Infection.

Outcomes

Primary Outcomes

Freedom from Atrial Arrhythmia Recurrence at 12 Months

Time Frame: 12 months after ablation procedure

Proportion of participants free from atrial fibrillation/atrial flutter/atrial tachycardia recurrence at 12 months post-ablation.

Secondary Outcomes

  • Procedural Safety(From enrollment to completion of follow-up(at least 12 months))
  • Symptom Relief and Quality of Life Enhancement.(From enrollment to completion of follow-up(at least 12 months))
  • Atrial Fibrillation Burden Reduction(From enrollment to completion of follow-up(at least 12 months))

Study Sites (1)

Loading locations...

Similar Trials